Sanofi (SNYNF) FDA Approvals

Sanofi logo
$96.45 -0.36 (-0.37%)
As of 03:14 PM Eastern

Sanofi's Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Sanofi (SNYNF). Over the past two years, Sanofi has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Libtayo. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Libtayo (cemiplimab) FDA Regulatory Events

Libtayo (cemiplimab) is a drug developed by Sanofi for the following indication: Advanced Cervical Cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Sanofi FDA Events - Frequently Asked Questions

As of now, Sanofi (SNYNF) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Sanofi (SNYNF) has reported FDA regulatory activity for Libtayo (cemiplimab).

The most recent FDA-related event for Sanofi occurred on October 25, 2026, involving Libtayo (cemiplimab). The update was categorized as "Data," with the company reporting: "Regeneron Pharmaceuticals, Inc announced longer-term data reflecting nearly four years of follow-up from the Phase 3 C-POST trial evaluating PD-1 inhibitor Libtayo® (cemiplimab) as adjuvant treatment for patients with cutaneous squamous cell carcinoma (CSCC) at a high risk of recurrence after surgery and radiation."

Currently, Sanofi has one therapy (Libtayo (cemiplimab)) targeting the following condition: Advanced Cervical Cancer.

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for OTCMKTS:SNYNF last updated on 10/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners